Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia

NCT01743820 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01743820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01743820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
December 31, 2014
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria